NDAORALTABLETPriority Review
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAZVERIK (tazemetostat hydrobromide) is an oral small-molecule EZH2 inhibitor approved in June 2020 for treating certain hematologic malignancies characterized by EZH2 mutations or loss of SY1 expression. It represents a precision-medicine approach targeting epigenetic dysregulation in select patient populations.
Peak
Peak-stage product with moderate competitive pressure (30%) indicates stable commercial infrastructure and established market position, suggesting mid-to-large brand team engagement.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TAZVERIK currently shows zero linked job openings, suggesting a mature or fully-staffed commercial team. Opportunities may exist in medical affairs, market access, or specialty oncology sales, particularly if indication expansion accelerates.
Brand ManagerMedical Science Liaison
Worked on TAZVERIK at Epizyme, Inc.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.